50735-34-7

Basic information

• Product Name: Methyl 2-amino-5-bromonicotinate
• Synonyms: METHYL 2-AMINO-5-BROMONICOTINATE;METHYL 2-AMINO-5-BROMOPYRIDINE-3-CARBOXYLATE;2-AMINO-5-BROMO-NICOTINIC ACID METHYL ESTER;METHYL 2-AMINO-5-BROMONICOTINAT;3-Pyridinecarboxylic acid, 2-aMino-5-broMo-, Methyl ester;2-AMino-5-broMo-nicotinic acid ethyl ester;Methyl 2-amino-5-bromopyridine-3-carboxylate, 2-Amino-5-bromo-3-(methoxycarbonyl)pyridine
• CAS NO: 50735-34-7
• Molecular Formula: C₇H₇BrN₂O₂
• Molecular Weight: 231.05
• Product Categories: Pyridine;Heterocycle-Pyridine series
• Mol File: 50735-34-7.mol

Chemical Properties

• Melting Point: 143-146°C
• Boiling Point: 275.2 °C at 760 mmHg
• Flash Point: 120.3 °C
• Appearance: /
• Density: 1.662 g/cm³
• Vapor Pressure: 0.00515mmHg at 25°C
• Refractive Index: 1.607
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.45±0.49(Predicted)
• CAS DataBase Reference: Methyl 2-amino-5-bromonicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-amino-5-bromonicotinate(50735-34-7)
• EPA Substance Registry System: Methyl 2-amino-5-bromonicotinate(50735-34-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 50735-34-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl 2-amino-5-bromonicotinate is used as a chemical reagent for the synthesis of pharmaceutical agents. Its unique structure allows it to be a valuable building block in the development of new drugs, particularly those targeting the central nervous system or other biological processes where nicotinic acid derivatives play a role.

InChI:InChI=1/C7H7BrN2O2/c1-12-7(11)5-2-4(8)3-10-6(5)9/h2-3H,1H3,(H2,9,10)

Upstream product

• 67-56-1 methanol 
• 52833-94-0 2-amino-5-bromonicotinicacid 
• 14667-47-1 methyl 2-aminonicotinate 
• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 52963-33-4 2-amino-5-bromonicotinic acid hydrobromide 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 1214380-83-2 methyl 2-amino-5-phenylpyridine-3-carboxylate 
• 1801262-20-3 6-bromo-[1,2,4]triazolo[1,5-a]pyridine-8-carboxylic acid methyl ester 
• 1217123-14-2 C₉H₉BrN₂O₃ 
• 1217123-38-0 C₁₁H₁₁BrN₂O₄ 
• 947249-44-7 methyl 2-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nicotinate 

Relevant articles and documents

Directing Group Enables Electrochemical Selectively Meta-Bromination of Pyridines under Mild Conditions

Without the use of catalysts and oxidants, a facile and sustainable electrochemical bromination protocol was developed. By introducing the directing groups, the regioselectivity of pyridine derivatives could be controlled at themeta-position utilizing the inexpensive and safe bromine salts at room temperature. A variety of brominated pyridine derivatives were obtained in 28-95% yields, and the reaction could be readily performed at a gram scale. By combining the installation and removing the directing group, the concept ofmeta-bromination of pyridines could be verified.

SUBSTITUTED INDOLE COMPOUNDS

Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A

Dual-specificity tyrosine phosphorylation-related kinase 1A (DYRK1A) is a dual-specificity protein kinase that catalyses phosphorylation and autophosphorylation. Higher DYRK1A expression correlates with cancer, in particular glioblastoma present within the brain. We report here the synthesis and biological evaluation of new heterocyclic diphenolic derivatives designed as novel DYRK1A inhibitors. The generation of these heterocycles such as benzimidazole, imidazole, naphthyridine, pyrazole-pyridines, bipyridine, and triazolopyrazines was made based on the structural modification of the lead DANDY and tested for their ability to inhibit DYRK1A. None of these derivatives showed significant DYRK1A inhibition but provide valuable knowledge around the importance of the 7-azaindole moiety. These data will be of use for developing further structure-activity relationship studies to improve the selective inhibition of DYRK1A.

NEW COMPOUNDS AND ORGANIC ELECTRONIC DEVICE CONTAINING THE SAME

The present invention relates to a novel compound and to an organic electronic device containing the same. According to the present invention, a compound having an extended conjugate length and excellent planarity is provided, and the organic electronic device containing the same, with the structural characteristics, can exhibit remarkable power-conversion efficiency by simultaneously realizing the improvement of the short circuit current density, the charging rate and the open-circuit voltage value.COPYRIGHT KIPO 2018

PHENYL-TRIAZOLO-PYRIDINE COMPOUNDS

The present invention provides a compound of the Formula (I) below: wherein R1 is selected from the group consisting of H, CH3, CN, —CH2CN, —C(CH3)2CN, F, Cl, and Br; R2 is selected from the group consisting of H, —O(C1-C3alkylene)R4, —CH2CN, CN, —OCH3, CF2, —C(CH3)2CN, —C(CH3)2, —S(O)2CH3, —S(O)2NH2, and —OCF2; R3 is selected from the group consisting of H, CH3, and —OCH3; and R4 is selected from the group consisting of H, —C(CH3)2CN, —OCH3, —S(O)2CH3, CN, and —C(CH3)2OH; or a pharmaceutical salt thereof, methods of treating type two diabetes using the compound and a process for preparing the compound.

AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS

Provided herein are aminopyridine derivatives and pharmaceutical compositions that are useful as TAM family kinase inhibitors.

THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME

In part, the present invention is directed towards compounds with FabI inhibiting properties. Such compounds may also inhibit other enzymes, including those similar to FabI either structurally or functionally, for example, Fab K. Kits and compositions that include the disclosed compounds are also provided. Methods of treating a subject with a bacterial illness is also disclosed.